-
Actinium Pharmaceuticals, Inc. NYSE MKT LLC:ATNM Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for its ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With its ARC approach, Actinium seeks to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Its lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SIERRA trial is over seventy-five percent enrolled and positive single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings. More information on this Phase 3 clinical trial can be found at sierratrial.com. I-131 apamistamab will also be studied as a targeted conditioning agent in a Phase 1 study with a CD19 CAR T-cell Therapy with Memorial Sloan Kettering Cancer Center and Phase 1/2 anti-HIV stem cell gene therapy with UC Davis. In addition, the company is developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Ongoing combination trials include its CD33 alpha ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax. Underpinning its clinical programs is its proprietary AWE (Antibody Warhead Enabling) technology platform. This is where its intellectual property portfolio of over 100 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster its pipeline for strategic purposes. Its AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc.
Location: 275 Madison Ave Fl 7, New York, 10016-1101, US | Website: www.actiniumpharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-30.91M
Cash
86.04M
Avg Qtr Burn
-8.49M
Short % of Float
4.79%
Insider Ownership
1.79%
Institutional Own.
29.57%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Iomab-B (CD45) (apamistamab-I-131) Details Hematopoietic cell transplantation , Acute myeloid leukemia | BLA Submission | |
Actimab-A + venetoclax Details Relapsed/refractory acute myeloid leukemia | Phase 1/2 Update | |
Iomab-ACT (CAR-T – CD45) Details Lymphoma, Diffuse large B cell lymphoma | Phase 1/2 Update | |
Actimab-A + CLAG-M Details Relapsed/refractory acute myeloid leukemia | Phase 1 Update | |
Iomab-ACT (CAR-T – CD45) Details Sickle cell disease, Blood disorder | Phase 1 Initiation | |
Iomab-ACT (GeneTx – CD45) Details Lymphoma, Acute radiation syndrome | Failed Discontinued | |
Actimab-A + venetoclax Details Myelodysplastic syndrome | Failed Discontinued |